Immunotherapy for advanced or recurrent endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether immunotherapy, a treatment that helps your immune system attack cancer cells, is effective against advanced or recurrent endometrial cancer. It aims to see how well the treatment works based on specific genetic markers in your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 or older
- A confirmed diagnosis of endometrial cancer that is one of these types: endometrioid, serous, clear cell, mixed, or carcinosarcoma
- The cancer is advanced (stage III or IV) or has come back after treatment, and you are scheduled for surgery or a biopsy as part of your care
- A tumor sample from that surgery or biopsy is stored for research
- A test shows your tumor is either mismatch-repair-deficient (dMMR) or -proficient (pMMR), meaning it has a specific genetic feature
- You have not had prior immunotherapy for another cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with endometrial cancer respond well to immunotherapy. It uses samples of your tumor to help doctors better understand how to choose the right treatment for each person.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether an immunotherapy combination can help shrink or control endometrial cancer so that surgery might not be needed. It is for people whose tumors have a specific genetic feature (dMMR/MSI-H) that may respond well to this treatment.
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a new medicine called QL1706 (a type of immunotherapy that helps your immune system fight cancer) combined with chemotherapy for women with advanced or recurrent endometrial cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help you live longer.
Hear when a new pMMR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.